What is HC Wainwright’s Estimate for PepGen Q1 Earnings?

PepGen Inc. (NASDAQ:PEPG) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for PepGen in a report released on Monday, February 24th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.75) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.74) EPS.

PEPG has been the subject of several other reports. Bank of America downgraded PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Monday, December 16th. Wedbush reduced their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

PepGen Price Performance

PEPG stock opened at $1.53 on Wednesday. The business has a 50-day moving average price of $2.41 and a 200 day moving average price of $5.75. The company has a market capitalization of $49.87 million, a P/E ratio of -0.51 and a beta of 1.53. PepGen has a 1-year low of $1.16 and a 1-year high of $19.30.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.13.

Hedge Funds Weigh In On PepGen

A number of large investors have recently added to or reduced their stakes in the company. RTW Investments LP bought a new position in PepGen in the fourth quarter worth about $12,102,000. Janus Henderson Group PLC raised its holdings in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after purchasing an additional 1,794,641 shares in the last quarter. Suvretta Capital Management LLC increased its holdings in shares of PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after acquiring an additional 140,000 shares in the last quarter. Northern Trust Corp increased its holdings in shares of PepGen by 5.4% during the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock valued at $595,000 after acquiring an additional 7,984 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of PepGen by 1,033.2% during the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock valued at $594,000 after acquiring an additional 142,814 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.